Skye Bioscience to Present Poster at Keystone Obesity Conference

Skye Bioscience, Inc. (Nasdaq: SKYE), a clinical-stage biotechnology company dedicated to developing innovative treatments for obesity and metabolic disorders, is set to present significant research at the Keystone Obesity Conference in San Diego. On January 28, 2026, Dr. Chris Twitty will showcase a poster titled "Investigating the Efficacy of Nimacimab Alone or in Combination with Tirzepatide, and as a Maintenance Therapy Post Tirzepatide Discontinuation in a Diet Induced Obesity (DIO) Mouse Model" during the poster session.

The poster will focus on nimacimab, a monoclonal antibody designed to inhibit the CB1 receptor in a peripherally-restricted manner, minimizing central nervous system penetration and the associated neuropsychiatric side effects that have plagued previous CB1-targeting drugs. The research aims to explore critical questions regarding nimacimab's potential to enhance the efficacy of incretin agonists, its durability in promoting weight loss following treatment cessation, its viability as a maintenance therapy after stopping tirzepatide, and the mechanisms underlying its weight loss effects.

Skye Bioscience is focused on advancing next-generation therapeutics through the modulation of G-protein coupled receptors, aiming to unlock new therapeutic pathways for metabolic health. Currently, the company is conducting a Phase 2a clinical trial assessing nimacimab's safety and efficacy in combination with the GLP-1 receptor agonist Wegovy®.

For more information about Skye Bioscience and its commitment to tackling obesity and metabolic health challenges, please visit their website and connect with them on social media platforms like X and LinkedIn. Investor relations can be reached for inquiries via email.

As Skye Bioscience, Inc. (Nasdaq: SKYE) prepares to present at the upcoming Keystone Obesity Conference, investors should pay close attention to the developing narrative surrounding its lead candidate, nimacimab. As a peripherally-restricted CB1-inhibitor monoclonal antibody, nimacimab offers the potential for a transformative approach to obesity treatment with a focus on mitigating the adverse neuropsychiatric effects associated with previous CB1 antagonists.

The poster presentation is likely to generate buzz, especially with intriguing questions about nimacimab's efficacy when combined with incretin agonists like tirzepatide, and its viability as a maintenance therapy post-tirzepatide treatment. Given the competitive landscape of obesity therapeutics, Skye's findings could be pivotal in positioning nimacimab as a valuable adjunct or alternative in treatment regimens.

From a market perspective, ongoing or favorable results relating to nimacimab's durability of effect on weight loss and its potential mechanism of action – independent of caloric restriction – could enhance investor sentiment. The Launched studies examining its additive effects with GLP-1 receptor agonists underscore the strategic approach that Skye is undertaking.

Investors should monitor Skye Bioscience closely for updates on their Phase 2a clinical trial, particularly as results may influence stock performance. If nimacimab shows significant promise in its therapeutic role, it could lead to partnerships or acquisitions, given the high demand for effective obesity treatments.

In conclusion, keeping an eye on the upcoming conference presentation, clinical trial progress, and overall market conditions for obesity therapies will be crucial. With nimacimab’s novel mechanism and potential benefits, Skye could be positioning itself favorably in a rapidly evolving market.